Clinical trials drive therapeutic innovation but often underrepresent populations most affected by the disease. Despite efforts to include women, minorities, and children, participation still lags behind intent. Ensuring equitable representation is essential to maximize the impact of new therapies. This perspective offers actionable insights from a diverse panel—including patients, clinicians, researchers, and advocates—shared during the 2025 American Society for Clinical Pharmacology and Therapeutics Patient Forum.
Stancil et al. (Tue,) studied this question.